SGMO NT 10-Q: Late filing
Sangamo Therapeutics
Filed with the SEC on · accession 0001193125-26-354282
SGMO filed a NT 10-Q (nt 10-q) with the SEC on Aug 17, 2026. A report the company filed with the SEC (the US market regulator).
Summary of the filing
Sangamo Therapeutics filed a Form NT 10-Q indicating it cannot timely file its quarterly report for the period ended June 30, 2026 due to its Chapter 11 bankruptcy filing and lack of an independent accounting firm.
Key details
✦ Ask GOAX AI about this filing — what it means for SGMO, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for SGMO?
Click hereFrequently asked questions
What did SGMO file with the SEC on Aug 17, 2026?
SGMO filed a NT 10-Q (Late filing). Sangamo Therapeutics filed a Form NT 10-Q indicating it cannot timely file its quarterly report for the period ended June 30, 2026 due to its Chapter 11 bankruptcy filing and lack of an independent accounting firm.
What does a late filing mean for SGMO stock?
The stock often falls sharply. In a Chapter 11 reorganization existing shares are frequently cancelled or heavily diluted; in Chapter 7 the company is liquidated and shareholders are paid last, usually nothing.
How do I read a NT 10-Q?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A NT 10-Q (nt 10-q): A report the company filed with the SEC (the US market regulator).
Other SGMO SEC filings
Get alerts when SGMO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days